<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="104295">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02014961</url>
  </required_header>
  <id_info>
    <org_study_id>METC 13-1-001</org_study_id>
    <nct_id>NCT02014961</nct_id>
  </id_info>
  <brief_title>Worm Study: Modifier Genes in Sudden Cardiac Death</brief_title>
  <official_title>Worm Study: Identification of Modifier Genes in a Unique Founder Population With Sudden Cardiac Death</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Netherlands Heart Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <authority>The Netherlands: The Central Committee on Research Involving Human Subjects</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In a large Dutch SCN5A founder population with malignant ventricular arrhythmias, the
      investigators aim to identify genetic modifiers by means of whole-exome sequencing and to
      establish a comprehensive genotype-phenotype correlation, focussing on clinical and cellular
      electrophysiological characteristics and neurocardiac modulation.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>July 2014</start_date>
  <primary_completion_date type="Anticipated">July 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case Control, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Difference in genetic profile (e.g. modifier genes) between mutation carriers expressing different phenotypes and non-mutation carriers.</measure>
    <time_frame>two years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Brugada Syndrome</condition>
  <condition>Long QT Syndrome 3</condition>
  <arm_group>
    <arm_group_label>Mutation Carriers</arm_group_label>
    <description>Ajmaline challenge 1mg/kg in 5 minutes Whole-exome sequencing Dermal biopsy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-Mutation Carriers</arm_group_label>
    <description>Whole-exome sequencing</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Dermal biopsy</intervention_name>
    <arm_group_label>Mutation Carriers</arm_group_label>
    <arm_group_label>Non-Mutation Carriers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ajmaline challenge</intervention_name>
    <arm_group_label>Mutation Carriers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Whole-exome sequencing</intervention_name>
    <arm_group_label>Mutation Carriers</arm_group_label>
    <arm_group_label>Non-Mutation Carriers</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Dutch founder population with SCN5A mutation.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria (mutation carrier group):

          -  Age &gt; 18 years.

          -  Confirmed kinship by haplotype analysis using predefined microsatellite markers.

          -  Heterozygous or homozygous presence of the SCN5A delPhe1617 mutation.

          -  Any SCN5A H588 variant (wild type, H558R-heterozygous or homozygous).

          -  Written informed consent.

        Inclusion Criteria (non-mutation carrier group):

          -  Age &gt; 18 years.

          -  Confirmed kinship by haplotype analysis using predefined microsatellite markers.

          -  Both parents of a mutation carrier can be included.

          -  SCN5A wild type.

          -  Any SCN5A H588 variant (wild type, H558R-heterozygous or homozygous).

          -  Written informed consent.

        Exclusion Criteria:

          -  Age &lt; 18 years.

          -  Non-SCN5A delPhe1617 mutation or SCN5A wild type.

          -  No confirmed kinship to founder population.

          -  Inability or declination to give informed consent.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul G.A. Volders, M.D., Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Maastricht University Medical Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rachel M.A. ter Bekke, M.D.</last_name>
    <phone>+31433877098</phone>
    <email>rachel.ter.bekke@mumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Paul G.A. Volders, M.D., Ph.D.</last_name>
    <phone>+31433877097</phone>
    <email>p.volders@maastrichtuniversity.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Maastricht University Medical Center</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <zip>6202 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>ter Bekke</last_name>
      <phone>+31433877098</phone>
      <email>rachel.ter.bekke@mumc.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 26, 2014</lastchanged_date>
  <firstreceived_date>December 9, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Long QT Syndrome</mesh_term>
    <mesh_term>Death, Sudden, Cardiac</mesh_term>
    <mesh_term>Death</mesh_term>
    <mesh_term>Brugada Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ajmaline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
